CCDC110 inhibitors encompasses a range of compounds designed to specifically target and inhibit the function of the CCDC110 protein. The CCDC110 protein, encoded by the CCDC110 gene, is implicated in a variety of cellular processes, although the full extent of its biological roles may not be fully understood. Inhibitors in this class bind to the CCDC110 protein at specific sites, which are crucial for its activity, thereby preventing it from performing its normal function within the cell. The inhibition mechanism can involve either competitive or non-competitive interactions, where the inhibitor molecules may compete with natural substrates or ligands for binding sites or alternatively bind to allosteric sites that induce a conformational change in the protein structure, rendering it inactive. The specific molecular architecture of these inhibitors is designed to ensure a high affinity for the CCDC110 protein, maximizing the efficacy of inhibition.
Each inhibitor within the CCDC110 inhibitors class operates by engaging with the CCDC110 protein in a unique manner. The precision of this interaction is a result of the rigorous design of inhibitor molecules to align with the protein's structure. The binding of these inhibitors can lead to a cessation of the protein's normal activity, which is often a critical factor in the regulation of downstream signaling pathways. The impact on these pathways is a direct consequence of CCDC110 inhibition, which can lead to a cascade of cellular effects and alterations in cellular homeostasis. Through the strategic design of these chemical compounds, the inhibitors can exert a selective and potent effect on the CCDC110 protein function, thus providing a means to study the role of CCDC110 in cellular processes and potentially influence those processes based on the protein's activity profile. The specificity and selectivity of these inhibitors are paramount, ensuring minimal off-target effects and a clear focus on the CCDC110 protein's activity within its native biological context.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Binds to FKBP12 and inhibits mTOR, a kinase that regulates cell growth, which may decrease CCDC110 expression due to reduced cellular growth signals. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor that prevents Akt activation, potentially reducing the phosphorylation and activity of downstream proteins which could include CCDC110. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
An HDAC inhibitor that alters chromatin structure, potentially influencing the transcription of genes including that of CCDC110. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
A MEK inhibitor that interferes with the ERK/MAPK pathway, possibly affecting CCDC110 activity by modulating signaling pathways that regulate its function. | ||||||
Wiskostatin | 253449-04-6 | sc-204399 sc-204399A sc-204399B sc-204399C | 1 mg 5 mg 25 mg 50 mg | $48.00 $122.00 $432.00 $812.00 | 4 | |
A GLUT1 inhibitor that impedes glucose uptake, which could indirectly decrease the energy supply necessary for CCDC110 activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, which may reduce the activity of transcription factors that regulate CCDC110 expression. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
A proteasome inhibitor that can lead to decreased protein levels of many proteins, potentially including CCDC110 due to increased protein degradation. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
An inhibitor of the TGF-beta receptor, which might reduce CCDC110 activity by interfering with TGF-beta signaling pathways. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
A ROCK inhibitor that might affect the stability and localization of CCDC110 by altering actin cytoskeleton dynamics. | ||||||
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $35.00 $115.00 $515.00 | 26 | |
A tankyrase inhibitor that stabilizes axin and inhibits Wnt signaling, potentially decreasing CCDC110 expression if it is Wnt-responsive. | ||||||